Lificiguat

Lificiguat binds to the β subunit of soluble guanylyl cyclase (sGC) with Kd of 0.6-1.1 μM in the presence of CO.

Product Specifications

CAS Number

[170632-47-0]

Product Name Alternative

YC-1

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Guanylate Cyclase

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Lificiguat.html

Concentration

10mM

Purity

99.70

Solubility

DMSO : ≥ 100 mg/mL

Smiles

OCC1=CC=C(C2=NN(CC3=CC=CC=C3)C4=C2C=CC=C4)O1

Molecular Formula

C19H16N2O2

Molecular Weight

304.34

Precautions

H302, H315, H319, H335

References & Citations

[1]Purohit R, et al. YC-1 binding to the β subunit of soluble guanylyl cyclase overcomes allosteric inhibition by the α subunit. Biochemistry. 2014 Jan 14;53 (1) :101-14.|[2]Kong J, et al. YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma. Mol Cancer. 2014 Jan 13;13:7.|[3]Chang LC, et al. YC-1 inhibits proliferation of breast cancer cells by down-regulating EZH2 expression via activation of c-Cbl and ERK. Br J Pharmacol. 2014 Sep;171 (17) :4010-25.|[4]Komsuoglu Celikyurt I, et al. Effects of YC-1 on Learning and Memory Functions of Aged Rats. Med Sci Monit Basic Res. 2014 Aug 21;20:130-7.